http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-5580817-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24e76490bed88751680a5fef9bc73892 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C217-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C215-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-133 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C213-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C217-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 |
| filingDate | 2004-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_483bc335f26a2a1ec51465c7659e71e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcec3372ebad18303e98a45f21eb1c51 |
| publicationDate | 2005-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-5580817-A2 |
| titleOfInvention | VENLAFAXINE CHLORIDEHYDRATE MONOHIDRATE AND METHODS FOR THE PREPARATION OF THE SAME |
| abstract | 1.- The venlafaxine hydrochloride monohydrate. 2.- The substantially pure venlafaxine hydrochloride monohydrate. 4.- The venlafaxine hydrochloride monohydrate that exhibits a powder X-ray diffraction pattern that has characteristic peaks expressed in grades 2. ? at around 7.45, 8.60, 12.93, 14.95, 15.54, 15.84, 16.43, 17.53, 18.02, 18.58, 18.80, 19.54, 20.05, 20.51, 21.41, 22.46, 23.07, 23.52, 24.08, 24.70, 25.44, 26.54, 27.07, 28.29 , 30.60, 31.37, 32.25, 32.74, 34.04, and 34.60.6.- A pharmaceutical composition comprising a therapeutically effective amount of a venlafaxine hydrochloride monohydrate and a pharmaceutically acceptable carrier or diluent. 8. The pharmaceutical composition of the claim 6, wherein the pharmaceutical composition contains less than 1% by weight of crystalline polymorphs of venlafaxine hydrochloride other than venlafaxine hydrochloride monohydrate, based on 100% of the total weight of venlafaxine hydrochloride in the pharmaceutical composition. 26.- A method for preparing venlafaxine hydrochloride monohydrate comprising recrystallizing form I or II from venlafaxine hydrochloride or a mixture thereof in water or in a mixture of water and one or more organic solvents cos. |
| priorityDate | 2001-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.